OBJECTIVES: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. METHODS: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. RESULTS:Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). CONCLUSIONS: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.
RCT Entities:
OBJECTIVES: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. METHODS: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. RESULTS: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). CONCLUSIONS: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.
Authors: Antoine Chaillon; Sara Gianella; Steven M Lada; Josué Perez-Santiago; Parris Jordan; Caroline Ignacio; Maile Karris; Douglas D Richman; Sanjay R Mehta; Susan J Little; Joel O Wertheim; Davey M Smith Journal: J Virol Date: 2018-01-17 Impact factor: 5.103
Authors: Anita Rachlis; Marianne Harris; Richard Lalonde; Stephen D Shafran; Cécile Tremblay; Mark A Wainberg; Sharon Walmsley Journal: Can J Infect Dis Med Microbiol Date: 2010 Impact factor: 2.471
Authors: Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman Journal: PLoS One Date: 2010-10-06 Impact factor: 3.240
Authors: James H Willig; Sara-Anne Wilkins; Ashutosh Tamhane; Christa R Nevin; Michael J Mugavero; James L Raper; Laura A Napolitano; Michael S Saag Journal: AIDS Res Hum Retroviruses Date: 2012-09-05 Impact factor: 2.205